What does this research mean for the field?

Empagliflozin does not improve VO2 max, physical activity levels, or quality of life in elderly individuals with overweight or obesity who are at risk of heart failure. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the effects of empagliflozin on aerobic capacity and quality of life in elderly individuals at risk for heart failure.

March 12, 2026Open Access

Empagliflozin and Functional Aerobic Capacity in Individuals with Increased Risk of Heart Failure: The Empire Prevent Cardiac Trial

Resultado clave

Empagliflozin did not improve VO2 max, physical activity level, or quality of life in elderly individuals at risk of heart failure.

Puntos clave

To evaluate the effects of empagliflozin on aerobic capacity and quality of life in elderly individuals at risk for heart failure.
Randomized trial design
Population included elderly individuals with overweight or obesity
Measured outcomes included VO2 max, physical activity level, and quality of life
Statistical analysis of differences pre- and post-intervention
Empagliflozin did not significantly change VO2 max levels
No effect on physical activity levels was observed
Quality of life remained unchanged among participants

PICO estructurado

Does empagliflozin improve VO2 max, physical activity level or QoL in elderly individuals with overweight or obesity and risk of heart failure?

Población

Elderly individuals with overweight or obesity and risk of heart failure

Intervención

Empagliflozin

Resultado

VO2 max, physical activity level or QoLsurrogate

Empagliflozin does not improve functional aerobic capacity, physical activity, or quality of life in elderly patients with overweight or obesity at risk for heart failure.

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

Empagliflozin did not affect VO2 max, physical activity level or QoL in elderly individuals with overweight or obesity and risk of HF.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Larsen et al. (Sun,) reported a other. Empagliflozin did not improve VO2 max, physical activity level, or quality of life in elderly individuals at risk of heart failure.

synapsesocial.com/papers/69b2573196eeacc4fcec5bfe https://doi.org/https://doi.org/10.1016/j.ahj.2026.107398

Me gusta

Guardar

Ver artículo completo